Medical Doctor Program year 2024 Reported 2019–2024 Source: CMS Open Payments, 2026 publication

Luke Marone

Vascular Surgery Sandy Springs, GA Medical Doctor

NPI 1407820483 CMS profile 335432

20 Glenlake Pkwy, Sandy Springs, GA 30328

Open in the dashboard

General payments

$9,410

126 records reported · program years 2019–2024

Research payments

$1,170

Paid to them · 1 record reported · program years 2019–2024

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12,057 paid to institutions, not to them · program years 2019–2022

Through program year 2024, Luke Marone of Sandy Springs, GA is reported in the CMS Open Payments database as having received $9,410 across 126 general payments and $1,170 in research payments paid to them. Separately, studies naming them as principal investigator received $12,057 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 69th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2024 General $247 7
2023 General $147 7
2022 General $3,019 34
2021 General $1,561 23
2020 General $952 13
2020 Research $1,170 1
2019 General $3,484 42

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Luke Marone
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Luke Marone were reported at $0. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Luke Marone Vascular Surgery median Middle half National median
2019 $3,484 $796 $226–$2,363 $163
2020 $952 $348 $118–$1,110 $114
2021 $1,561 $471 $158–$1,421 $132
2022 $3,019 $725 $222–$2,183 $149
2023 $147 $836 $257–$2,440 $160
2024 $247 $909 $252–$2,619 $164
2025 $0 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2024
  1. Boston Scientific Corporation $2,692 24 payments
  2. Canon Medical Systems USA, Inc. $1,489 15 payments
  3. Medtronic, Inc. $1,149 16 payments
  4. W. L. Gore & Associates, Inc. $1,069 15 payments
  5. Medtronic Vascular, Inc. $836 10 payments
  6. Endologix, Inc. $608 9 payments
  7. Cook Medical LLC $409 7 payments
  8. Veryan Medical Incorporated $244 1 payment
  9. Shockwave Medical, Inc $164 1 payment
  10. Silk Road Medical, Inc. $139 2 payments
  11. Other $611 26 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2024
  1. Food and Beverage $7,175 117 payments
  2. Travel and Lodging $2,235 9 payments
Products named General payments · program years 2019–2024
  1. AngioJet Ultra 5000A $1,457 11 payments
  2. TurboHawk $577 5 payments
  3. HawkOne $383 5 payments
  4. IN.PACT Admiral $316 3 payments
  5. VIABAHN VBX Balloon Expandable Endoprosthesis $308 4 payments
  6. PROPATEN Vascular Graft $250 3 payments
  7. GENERAL BALLOONS $245 2 payments
  8. BioMimics $244 1 payment
  9. Ovation $234 3 payments
  10. Conformable TAG Thoracic Endoprosthesis $217 4 payments
  11. Other $4,118 82 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2024
  1. Philips Electronics North America Corporation $1,170 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 1 drug

Part D claims

17

Median for Vascular Surgery: 122

Drug cost

$257

Median for Vascular Surgery: $14,135

Branded share of claims

100%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Clopidogrel Clopidogrel Bisulfate Brand 17 $257

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 33 billing codes

Paid by Medicare

$12,908

Medicare's payments for the services billed

Medicare patients

42

Average age 71

Services billed

125

20 women, 22 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 52%
Diabetes 48%
Chronic kidney disease 48%
Ischemic heart disease 38%
Heart failure 31%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 8 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
MOUNJARO
  • Lilly USA, LLC $19
$19 — —
NP Thyroid 60
  • Acella Pharmaceuticals, LLC $13
$13 — —
AVYCAZ
  • AbbVie, Inc. $6
$6 — —
DALVANCE
  • AbbVie, Inc. $6
$6 — —
TEFLARO
  • AbbVie, Inc. $6
$6 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 8 in the dashboard with a free account

Records

127 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2024

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record